Background and Aim: 5-Aminosalicylates (ASA) are widely used in inflammatory bowel
INTRODUCTION
5-aminosalcylic acid (5-ASA) is recommended for both induction and maintenance therapy in ulcerative colitis (UC) at a dose from 1 to 4 grams per day. [1] [2] [3] [4] [5] Therefore, 5-ASA are widely used in UC and more than half of patients' are receiving oral 5-ASA treatment in the era of biologics. 6, 7 In a French referral center-based cohort, the probabilities of receiving oral mesalamine at 1 and 5 years from the time of UC diagnosis were 43.4% and 68.1%, respectively. 7 In Crohn's disease (CD), its efficacy remains controversial, but it is still used by some practitioners in this indication. 8 Nephrotoxic lesions due to high doses 5-ASA were first described in animal models. 9 Chronic renal failure was reported in human receiving sulphasalazine and salicylazosulfapyridine since the 1970s. 10-12 5-ASA-related nephrotoxicity occurs particularly within the first 12 months, even if delayed presentations after several years have also been described. 13 Such side effects usually take the form of an indolent, severe, chronic, and progressive interstitial nephritis. 14, 15 Restoration of renal function is leaded in 40%-85% of cases when the diagnosis is made within 10 months of starting treatment, thus suggesting the importance of an early biological diagnosis. [14] [15] [16] Patients with pre-existing renal impairment, concomitant potentially nephrotoxic drugs, or comorbidities should benefit from a scheduled renal function monitoring during 5-ASA therapy. 13, 17 European Crohn's and Colitis Organisation (ECCO) guidelines recommended creatinine and full blood count every 3-6 months in these patients. 17 However gastroenterologists' management of renal function during oral 5-ASA maintenance therapy in inflammatory bowel disease (IBD) patients in daily practice remains unknown.
We therefore performed a French national survey which aims at evaluating how private gastroenterologists monitor renal function and manage renal failure in IBD patients treated with oral 5-ASA therapy.
MATERIALS AND METHODS

Questionnaire
This was a web-based cross sectional national survey consisting of multiple-choice questions. The survey was administered anonymously from March 2011 to July 2011. The questionnaire was consulting on the CREGG web-page. An email invitation to fill in the questionnaire was sent to all CREGG members with a second mailing to increase response rate.
Statistical analysis
The data were entered into a database (Microsoft Office Excel). Proportions were expressed as percentages.
RESULTS
Between March 2011 and July 2011, invitations to participate to the survey were addressed by e-mail to 1565 private gastroenterologists who are all CREGG members. A total of 249 practitioners responded to the survey and were included in the analysis.
Monitoring of renal function
Eighty two per cent (n = 205) of gastroenterologists declared that they always monitor renal function in IBD patients treated with oral 5-ASA. Only one percent (n = 3) of responders never follow renal function (Table 1) .
Ninety per cent (n = 225) of gastroenterologists are evaluating Glomerular Filtration Rate (eGFR) using Modification of Diet in Renal Disease (MDRD) and 51% (n = 126) of them measure the Creatinine Clearance (CCr) using a 24-hours urine collection. Forty one per cent (n = 102) of responders are monitoring blood electrolytes. Practitioners are measuring the 24-hour urinary proteins rate and are using urinary strips in 39% (n = 96) and 22% (n = 54) of cases, respectively ( Table 1) .
Most of gastroenterologists monitor renal function-related parameters twice a year as 71%, 54%, 65%, 44%, and 39% of them declared evaluating MDRD, CCr, blood electrolytes, 24-hours urinary protein and urinary strips every 6 months, respectively (Figure 1 ).
Before starting 5-ASA oral treatment, 59% (n = 148) of gastroenterologists evaluated renal function and 29% (n = 72) of them never evaluated it ( Table 1) .
Management of renal dysfunction
An increase in the creatinine level from 30 to 50% leads to treatment discontinuation for 48%
(n = 119) of gastroenterologists, whereas 29% of them stop therapy when a 10-30% increase in creatinine level is observed (Table 2 ).
In case of elevated creatinine levels while on 5-ASA therapy, a nephrologic opinion is asked by 80% (n = 200) of responders. In case of elevated creatinine levels before initiating 5-ASA therapy, a nephrologic opinion is asked by 76% (n = 189) of gastroenterologists ( Table 2) .
DISCUSSION
This is the first survey evaluating monitoring of renal function and management of renal failure in IBD patients on 5-ASA therapy.
Long-term 5-ASA therapy is generally consider to be safe and the occurrence of severe adverse effects is rare, with an incidence of 1 in 4000 patients/year. 18 In a recent observational prospective study, renal impairment was observed in 2.2% of 1529 IBD patients, including both patients with and without concomitant 5-ASA treatment. 19 Indeed, IBD patients not using 5-ASA are also at risk of renal disease. 20 Guidelines recommended renal function monitoring. 5, 21, 22 In the present survey, most of private gastroenterologists followed these recommended creatinine levels twice a year. 22 About 50% of reported cases of 5-ASAinduced interstitial nephritis present within 1 year of treatment intiation. 14, 16, 23 American
College of Gastroenterology recommended to monitor serum creatinine at 3-6 months intervals during the first year of mesalamine treatment, and then annually thereafter; t the optimal monitoring schedule of serum creatinine in patients treated with mesalamine remains to be determined, as there is no evidence currently to suggest that the frequency of testing improves patient outcomes. 21 Finally, there is still no evidence to date that either test, or the frequency of testing, is effective in identifying patients at risk of developing 5-ASA-related renal impairment. 13 Given the large number of IBD patients treated with oral 5-ASA, further cost-effectiveness studies are also needed.
Surprisingly, whereas it is recommended to measure serum creatinine before initiating treatment with mesalamine or its prodrugs 21 , only 60% of practitioners evaluate renal function before starting 5-ASA treatment. Such baseline evaluation allows comparison with further values and should condition the initiation of a close monitoring under treatment.
It has been suggested that more attention may be needed for patients with chronic renal failure and IBD using 5-ASA. 24 In our study, 76% of gastroenterologists asked for nephrologic opinion before starting oral 5-ASA to those patients. There is a lack of data in the literature about the safety of 5-ASA compounds in IBD suffering from chronic renal failure. 13 There are several limitations inherent to our survey. First, only 14.8% of practitioners who have been mailed responded to the survey. Second, those who filled in the questionnaire might be more aware of 5-ASA-related renal side effects. This could lead to an overestimation of renal function monitoring in our study. However, only physicians managed IBD patients were asked for survey. In addition, it is known that a total of 680 gastroenterologists are managing IBD patients in France. 25 Hence, it can be estimated that almost 40% of French gastroenterologists managing IBD patients responded to this survey. The strengths of our survey are the large number of responders and the fact that it was a nationwide survey.
Finally, the survey account for real life practice as it concerned only private practice gastroenterologists.
In conclusion, the majority of gastroenterologists use to monitor renal function once or twice 
